Last reviewed · How we verify
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life (PREV-IX_B)
HYPOTHESES: 1. That infants receiving PHiD-CV10 as a booster at 12 months of age, compared to controls having no PHiD-CV10 booster (i.e. standard PCV13), will have higher HiD antibody levels, lower carriage of NTHi, and less tympanic membrane perforation at 18 and 36 months of age. 2. That infants receiving PCV13 as a booster at 12 months of age, compared to controls having no PCV13 (i.e. PHiD-CV10 booster) will have higher antibody levels to serotypes 3, 6A and 19A, less carriage of these serotypes, and less tympanic membrane perforation at 18 and 36 months of age.
Details
| Lead sponsor | Menzies School of Health Research |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 261 |
| Start date | Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Oct 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Otitis Media
- Febrile Illness
- Cough
- Lower Respiratory Tract Infection
- Upper Respiratory Tract Infection
Interventions
- Prevenar13
- Synflorix
Countries
Australia